Since RAS proteins are common upstream regulators of both RAF-ERK and PI3K-AKT pathways, inhibition of RAS-signaling by RGS would be a desirable therapeutic approach for HCC treatment [2, 29, 30]. The gene discussed is AKT1; the disease is hepatocellular carcinoma.